U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT06859294) titled 'A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis' on Feb. 28.
Brief Summary: The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD).
Study participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period.
Study Start Date: March, 2025
Study Type: INTERV...